. 2020 Jan 17;10:530. doi: 10.1038/s41598-019-57380-0

Table 4.

Efficacy and Grade ≥ 3 AE between nab-paclitaxel vs sb-taxanes in each study region.

Efficacy	Study region	No. of studies	OR/HR (95% CI)	p-value	I² (%)
ORR^2–5,10	Western	2	2.03 (1.41–2.92)	<0.001^†	0
ORR^2–5,10	Eastern	2	1.80 (0.75–4.33)	0.19	79
DCR^3–5,10	Western	1	2.84 (1.37–5.89)	0.005^†	—
DCR^3–5,10	Eastern	2	1.91 (1.17–3.12)	0.01^†	0
PFS^2–5,10	Western	2	0.65 (0.44–0.96)	0.03^†	56
PFS^2–5,10	Eastern	2	0.96 (0.58–1.61)	0.88	73
OS^2–5,10	Western	2	0.85 (0.64–1.13)	0.27	44
OS^2–5,10	Eastern	2	0.86 (0.62–1.18)	0.35	0
Grade ≥ 3 AE
Neutropenia^2–5,10	Western	2	0.38 (0.26–0.54)	<0.001^†	93
Neutropenia^2–5,10	Eastern	2	0.75 (0.45–1.25)	0.27	91
Leukopenia^2,3,10	Western	1	0.75 (0.36–1.54)	0.43	—
Leukopenia^2,3,10	Eastern	2	0.41 (0.06–2.79)	0.36	93
Sensory neuropathy^2–5,10	Western	2	3.13 (1.23–7.94)	0.02^†	49
Sensory neuropathy^2–5,10	Eastern	2	2.59 (0.60–11.20)	0.20	73
Fatigue^2,4,5,10	Western	2	0.94 (0.04–23.37)	0.97	92
Fatigue^2,4,5,10	Eastern	1	3.03 (0.12–75.28)	0.50	—
DDR^3–5,10	Western	1	0.65 (0.29–1.48)	0.30	—
DDR^3–5,10	Eastern	2	0.75 (0.43–1.32)	0.32	0

^*Statistically significant with p < 0.05. Analyzed using random effects model.

Abbreviations: nab, nanoparticle albumin-bound; sb, solvent-based; OR, odds ratio (for ORR, DCR, AEs and DDR): HR, hazard ratio (for PFS and OS); –, not defined.